{
  "data": [
    {
      "id": "stat_N9Z2M3MV41KTJ8N3YA649A96JE",
      "url": "https://statorigin.org/stat/stat_N9Z2M3MV41KTJ8N3YA649A96JE",
      "indicator": {
        "slug": "health-sector-research-and-development-investment-growth-rate",
        "name": "Health sector research and development investment growth rate",
        "definition": "Annual percentage change in research and development investment by health sector companies."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "JP",
        "name": "Japan",
        "type": "country"
      },
      "period": {
        "start": "2024-01-01",
        "end": "2024-12-31",
        "type": "year"
      },
      "value": 9.1,
      "value_text": "9.1%",
      "unit": "percent",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "European Commission",
        "org_short_name": "European Commission",
        "org_url": "https://ec.europa.eu",
        "org_tier": 1,
        "document_title": "The 2025 EU Industrial R&D Investment Scoreboard",
        "document_url": "https://joint-research-centre.ec.europa.eu/jrc-news-and-updates/2025-eu-industrial-rd-investment-scoreboard-2025-12-22_en",
        "document_type": "press_release",
        "locator": "EU: Health and energy sectors shine in a year of slowdown",
        "quote": "EU companies in the health sector increased R&D investments by 13%, outperforming other regions such as the United States (7.1%), Japan (9.1%), and China (0.1%).",
        "published_date": "2025-12-22",
        "accessed_at": "2026-09-17",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T07:16:01.811Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "European Commission. (2025). The 2025 EU Industrial R&D Investment Scoreboard. Retrieved September 17, 2026, from https://joint-research-centre.ec.europa.eu/jrc-news-and-updates/2025-eu-industrial-rd-investment-scoreboard-2025-12-22_en. Via StatOrigin, https://statorigin.org/stat/stat_N9Z2M3MV41KTJ8N3YA649A96JE",
        "bibtex": "@misc{europeancommissi2025health9a96je,\n  author       = {{European Commission}},\n  title        = {The 2025 EU Industrial R\\&D Investment Scoreboard},\n  year         = {2025},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_N9Z2M3MV41KTJ8N3YA649A96JE},\n  note         = {Original source: https://joint-research-centre.ec.europa.eu/jrc-news-and-updates/2025-eu-industrial-rd-investment-scoreboard-2025-12-22\\_en. Accessed September 17, 2026.}\n}"
      },
      "updated_at": "2026-09-17T07:16:01.811Z"
    },
    {
      "id": "stat_B1EWGR1ZAMXV2PVS7F6YTM8M93",
      "url": "https://statorigin.org/stat/stat_B1EWGR1ZAMXV2PVS7F6YTM8M93",
      "indicator": {
        "slug": "median-drug-approval-time",
        "name": "Median drug approval time",
        "definition": "Median duration in days required by a regulatory authority to approve a new active substance application."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "JP",
        "name": "Japan",
        "type": "country"
      },
      "period": {
        "start": "2025-01-01",
        "end": "2025-12-31",
        "type": "year"
      },
      "value": 292,
      "value_text": "292 days",
      "unit": "days",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "Centre for Innovation in Regulatory Science",
        "org_short_name": "CIRS",
        "org_url": "https://cirsci.org",
        "org_tier": 3,
        "document_title": "New Drug Approvals by Six Major Authorities 2016-2025",
        "document_url": "https://cirsci.org/publications/cirs-rd-briefing-106-new-drug-approvals-by-six-major-authorities-2016-2025/",
        "document_type": "press_release",
        "locator": "Key Findings",
        "quote": "PMDA recorded the shortest median approval time in 2025 (292 days), followed by FDA (322 days), TGA (350 days), Health Canada (369 days), Swissmedic (413 days) and EMA (448 days).",
        "published_date": null,
        "accessed_at": "2026-09-17",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T16:36:08.269Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "Centre for Innovation in Regulatory Science. (2025). New Drug Approvals by Six Major Authorities 2016-2025. Retrieved September 17, 2026, from https://cirsci.org/publications/cirs-rd-briefing-106-new-drug-approvals-by-six-major-authorities-2016-2025/. Via StatOrigin, https://statorigin.org/stat/stat_B1EWGR1ZAMXV2PVS7F6YTM8M93",
        "bibtex": "@misc{cirs2025mediantm8m93,\n  author       = {{Centre for Innovation in Regulatory Science}},\n  title        = {New Drug Approvals by Six Major Authorities 2016-2025},\n  year         = {2025},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_B1EWGR1ZAMXV2PVS7F6YTM8M93},\n  note         = {Original source: https://cirsci.org/publications/cirs-rd-briefing-106-new-drug-approvals-by-six-major-authorities-2016-2025/. Accessed September 17, 2026.}\n}"
      },
      "updated_at": "2026-09-17T16:36:08.269Z"
    },
    {
      "id": "stat_84WCV23H6VE3N5JEVT5K316PE0",
      "url": "https://statorigin.org/stat/stat_84WCV23H6VE3N5JEVT5K316PE0",
      "indicator": {
        "slug": "new-active-substance-approvals",
        "name": "New active substance approvals",
        "definition": "Total count of new active substance marketing approvals granted by regulatory authorities during the period."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "JP",
        "name": "Japan",
        "type": "country"
      },
      "period": {
        "start": "2025-01-01",
        "end": "2025-12-31",
        "type": "year"
      },
      "value": 40,
      "value_text": "40",
      "unit": "count",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "Centre for Innovation in Regulatory Science",
        "org_short_name": "CIRS",
        "org_url": "https://cirsci.org",
        "org_tier": 3,
        "document_title": "New Drug Approvals by Six Major Authorities 2016-2025",
        "document_url": "https://cirsci.org/publications/cirs-rd-briefing-106-new-drug-approvals-by-six-major-authorities-2016-2025/",
        "document_type": "press_release",
        "locator": "Key Findings",
        "quote": "In 2025, FDA granted the highest number of new active substance approvals (50), followed by Health Canada (44), TGA (42), PMDA (40), EMA (39), and Swissmedic (34).",
        "published_date": null,
        "accessed_at": "2026-09-17",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T16:36:08.269Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "Centre for Innovation in Regulatory Science. (2025). New Drug Approvals by Six Major Authorities 2016-2025. Retrieved September 17, 2026, from https://cirsci.org/publications/cirs-rd-briefing-106-new-drug-approvals-by-six-major-authorities-2016-2025/. Via StatOrigin, https://statorigin.org/stat/stat_84WCV23H6VE3N5JEVT5K316PE0",
        "bibtex": "@misc{cirs2025active316pe0,\n  author       = {{Centre for Innovation in Regulatory Science}},\n  title        = {New Drug Approvals by Six Major Authorities 2016-2025},\n  year         = {2025},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_84WCV23H6VE3N5JEVT5K316PE0},\n  note         = {Original source: https://cirsci.org/publications/cirs-rd-briefing-106-new-drug-approvals-by-six-major-authorities-2016-2025/. Accessed September 17, 2026.}\n}"
      },
      "updated_at": "2026-09-17T16:36:08.269Z"
    },
    {
      "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGEB",
      "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEB",
      "indicator": {
        "slug": "sales-growth-at-constant-exchange-rates",
        "name": "Sales growth at constant exchange rates",
        "definition": "Percentage change in sales calculated at constant exchange rates over the specified period."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "JP",
        "name": "Japan",
        "type": "country"
      },
      "period": {
        "start": "2026-01-01",
        "end": "2026-06-30",
        "type": "quarter"
      },
      "value": 11,
      "value_text": "+11%",
      "unit": "percent",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "Roche",
        "org_short_name": "Roche",
        "org_url": "https://www.roche.com",
        "org_tier": 2,
        "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...",
        "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23",
        "document_type": "press_release",
        "locator": "Group results",
        "quote": "In Japan, sales were +11% at CER, -5% when reported in CHF, mainly due to product supply to third parties, as well as the uptake of Elevidys (Duchenne muscular dystrophy) and continued growth of Lunsumio (blood cancer), Vabysmo and Hemlibra.",
        "published_date": "2026-07-23",
        "accessed_at": "2026-09-15",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-15T22:15:46.809Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEB",
        "bibtex": "@misc{roche2026salesbjmgeb,\n  author       = {{Roche}},\n  title        = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n  year         = {2026},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEB},\n  note         = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}"
      },
      "updated_at": "2026-09-15T22:15:46.809Z"
    },
    {
      "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGEC",
      "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEC",
      "indicator": {
        "slug": "sales-growth-in-swiss-francs",
        "name": "Sales growth in Swiss francs",
        "definition": "Percentage change in sales reported in Swiss francs over the specified period."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "JP",
        "name": "Japan",
        "type": "country"
      },
      "period": {
        "start": "2026-01-01",
        "end": "2026-06-30",
        "type": "quarter"
      },
      "value": -5,
      "value_text": "-5%",
      "unit": "percent",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "Roche",
        "org_short_name": "Roche",
        "org_url": "https://www.roche.com",
        "org_tier": 2,
        "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...",
        "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23",
        "document_type": "press_release",
        "locator": "Group results",
        "quote": "In Japan, sales were +11% at CER, -5% when reported in CHF, mainly due to product supply to third parties, as well as the uptake of Elevidys (Duchenne muscular dystrophy) and continued growth of Lunsumio (blood cancer), Vabysmo and Hemlibra.",
        "published_date": "2026-07-23",
        "accessed_at": "2026-09-15",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-15T22:15:46.809Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEC",
        "bibtex": "@misc{roche2026salesbjmgec,\n  author       = {{Roche}},\n  title        = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n  year         = {2026},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEC},\n  note         = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}"
      },
      "updated_at": "2026-09-15T22:15:46.809Z"
    }
  ],
  "meta": {
    "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.",
    "license": "https://creativecommons.org/licenses/by/4.0/",
    "docs": "https://statorigin.org/docs/api",
    "total": 5,
    "limit": 50,
    "next_cursor": null
  }
}